Clinical Trial Update: A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) [Phase 2]

View source ↗

Summary

Results from a Phase 2 trial evaluating the safety and efficacy of survodutide (BI456906) in adults with non-alcoholic steatohepatitis and fibrosis (F1-F3) have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• Survodutide (BI456906)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2024-12-03